Ahead of an expected merger, the combined company of Amneal-plus-Impax has a new CEO. The drugmaker lured Allergan Chief Operating Officer Robert Stewart away to be its next leader during a tough time for the generics industry. More: Bisaro, Amneal poach
read moreUS regulators are undertaking a speedy review of AstraZeneca’s application to market Tagrisso as first-line treatment for lung cancer. More: US priority review for AZ’ Tagrisso Source: News
read moreGermany’s Boehringer Ingelheim and Cambridge, UK-based Autifony Therapeutics have announced a new collaboration focused on a novel therapeutic approach to a range of CNS disorders. More: New CNS partnership between Boehringer and Autifony Source: News
read moreCambridge, UK-based Horizon Discovery has expanded its relationship with Roche Diagnostics with a new agreement to assist in the development of immunohistochemistry (IHC) assays. More: Horizon expands agreement with Roche Diagnostics Source: News
read morePfizer Xeljanz and Xeljanz XR have received US marketing clearance for the treatment of adults with active psoriatic arthritis who have failed to respond or are intolerant to methotrexate or other disease-modifying antirheumatic drugs. More: Pfizer’s Xeljanz wins US nod
read moreSeven therapies have been put forward for approval in the European Union, bringing closer new options for a range of conditions including Crohn’s disease, diabetes and cancer. More: Seven therapies backed for EU approval Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals